Principal Investigator
Gabriel Contreras
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20220425
Clinical Trial Summary
A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
Phase
Phase II
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Carlos Bidot
Phone Number
+1 (305) 2438793
Email
cbidot2@miami.edu